Researcher.Life Logo

Annals of the Rheumatic Diseases : Impact Factor & More

eISSN: 1468-2060pISSN: 0003-4967

Aims and Scope of Annals of the Rheumatic Diseases

The Annals of the Rheumatic Diseases is a peer-reviewed medical journal. It is co-owned by the BMJ Group and the European League Against Rheumatism and covers all aspects of rheumatology, including musculoskeletal conditions, arthritis, and connective tissue diseases. The journal publishes basic, clinical, and translational research and abstracts from conferences. The journal was established in 1939. It is available online by subscription and archived editions of the journal (older than one year) are available free of charge. Each issue, the editor-in-chief selects a paper to be published open access as an "Editors Choice". The editor-in-chief is Josef Smolen. Less

Key Metrics

CiteScore
28.5
Eigenfactor
0.05 - 0.1
H-Index
272
Impact Factor
>= 25
Scite Index
0.88 5-Year SI
SJR
Q1Immunology
SNIP
5.22
Recommended pre-submission checks
Powered by Paperpal by Editage

Topics Covered on Annals of the Rheumatic Diseases

Annals of the Rheumatic Diseases Journal Specifications

Overview
Publisher BMJ PUBLISHING GROUP
Language English
Frequency Monthly
General Details
LanguageEnglish
FrequencyMonthly
Publication Start Year1935
Publisher URLVisit website
Website URLVisit website
View less

Planning to publish in Annals of the Rheumatic Diseases ?

Upload your Manuscript to get

  • Degree of match
  • Common matching concepts
  • Additional journal recommendations
Free Report

Recently Published Papers in Annals of the Rheumatic Diseases

A pathogenic gut lipoglycan drives systemic thromboinflammation in lupus nephritis.
  • 23 Apr 2027
  • Annals of the rheumatic diseases
Efficacy and safety of mufemilast in patients with Behçet's syndrome: a phase 2 randomised clinical trial.
  • 1 Jul 2026
  • Annals of the rheumatic diseases
Comorbidities in parents of individuals with congenital heart block: a Swedish nationwide study.
  • 1 Jul 2026
  • Annals of the rheumatic diseases
Response to correspondence on 'The incidence of interstitial lung disease in patients with systemic sclerosis' by Petelytska et al.
  • 1 Jul 2026
  • Annals of the rheumatic diseases
Response to correspondence on 'Gain of function NOTCH4 variants disrupt angiogenesis in systemic sclerosis' by Kaundal et al.
  • 1 Jul 2026
  • Annals of the rheumatic diseases
Commentary on 'Assessing the performance of AI chatbots in answering patients common questions about low back pain'.
  • 1 Jul 2026
  • Annals of the rheumatic diseases
A pathogenic gut lipoglycan drives systemic thromboinflammation in lupus nephritis.
  • 23 Apr 2027
  • Annals of the rheumatic diseases
Efficacy and safety of mufemilast in patients with Behçet's syndrome: a phase 2 randomised clinical trial.
  • 1 Jul 2026
  • Annals of the rheumatic diseases
Comorbidities in parents of individuals with congenital heart block: a Swedish nationwide study.
  • 1 Jul 2026
  • Annals of the rheumatic diseases
Response to correspondence on 'The incidence of interstitial lung disease in patients with systemic sclerosis' by Petelytska et al.
  • 1 Jul 2026
  • Annals of the rheumatic diseases
Response to correspondence on 'Gain of function NOTCH4 variants disrupt angiogenesis in systemic sclerosis' by Kaundal et al.
  • 1 Jul 2026
  • Annals of the rheumatic diseases
Commentary on 'Assessing the performance of AI chatbots in answering patients common questions about low back pain'.
  • 1 Jul 2026
  • Annals of the rheumatic diseases

FAQs on Annals of the Rheumatic Diseases